Table 3.

PPBs among different in vitro samples grouped by C_t.

Sample type	Ct	Cp	n	PPB%	p		Cu	p
	(ng/ml)	(g/L)		(Mean ± SD)			(ng/ml)
VRC spiked with human blank plasma	Total	–	80	58.0 ± 4.7	–		–	–
	25,000		14	61.6 ± 3.1	25 vs. 16	0.012	6777 ± 874	–
	16,000		22	58.7 ± 3.9	16 vs. 0.4	0.010	4825 ± 888
	1,500		21	57.8 ± 3.4			481.5 ± 96.5
	400		23	55.4 ± 5.6	0.4 vs. 25	<0.01	118.4 ± 19.8
VRC spiked with human ALB	Total		42	42.9 ± 6.3	–		–	–
	25,000	Total	24	43.7 ± 6.8	–		6391 ± 357	–
		30	8	36.8 ± 6.0	30 vs. 40	0.001	6459 ± 410	>0.05
		40	8	45.5 ± 4.1			6300 ± 208
		50	8	48.7 ± 3.9	50 vs. 30	<0.01	6416 ± 437
	400	Total	18	41.9 ± 5.4	–		110.8 ± 10.8	–
		30	6	44.2 ± 6.6	>0.05		109.5 ± 5.3	>0.05
		40	6	39.0 ± 4.6			113.6 ± 13.5
		50	6	42.5 ± 4.3			109.3 ± 13.1
VRC spiked with human AAG	Total		36	46.5 ± 7.6	–		–	–
	25,000	Total	18	45.5 ± 8.8	–		6690 ± 729	–
		0.01	6	36.9 ± 7.7	0.01 vs. 0.1	0.015	7305 ± 435	0.01 vs. 1	<0.01
		0.1	6	45.6 ± 4.0	0.1 vs. 1	0.018	6946 ± 338	0.1 vs. 1	<0.01
		1	6	54.0 ± 3.7	1 vs. 0.01	<0.01	5817 ± 240
	400	Total	18	47.5 ± 6.3	–		105.2 ± 6.8	–
		0.01	6	40.9 ± 3.3	0.01 vs. 0.1	0.003	108.9 ± 4.2	>0.05
		0.1	6	50.0 ± 2.8			100.1 ± 2.5
		1	6	51.5 ± 6.3	1 vs. 0.01	0.001	106.5 ± 9.0
VRC spiked with human GLB	Total	–	24	37.8 ± 4.1	–		–	–
	25,000	Total	12	36.2 ± 3.4	–		6859 ± 493
		10	6	35.2 ± 4.3	>0.05		7251 ± 338	0.001
		30	6	37.2 ± 2.0			6467 ± 224
	1,500	Total	12	39.4 ± 4.3	–		419.0 ± 22.1	–
		10	6	39.5 ± 2.7	>0.05		418.5 ± 20.9	>0.05
		30	6	39.4 ± 5.8			419.6 ± 25.2
VRC spiked with ALB+AAG+GLB	Total	–	24	56.1 ± 4.6	–		–	–
	25,000	Total	12	59.0 ± 2.9	–		6042 ± 82	–
		40.01	6	55.7 ± 0.9	<0.01		6009 ± 90	>0.05
		81	6	59.6 ± 1.6			6097 ± 72
	400	Total	12	53.2 ± 4.2	–		121.9 ± 5.6	–
		40.01	6	47.8 ± 1.4	<0.01		127.5 ± 4.2	<;0.01
		81	6	55.4 ± 1.5			117.0 ± 3.5

VRC, voriconazole; ALB, albumin; AAG, α1-acid glycoprotein; GLB, globulin; C_p, protein concentration; C_t, total drug concentration

PPB, plasma protein binding rate.